VAVanessa Abella

Vanessa Abella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vanessa Abella has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Morena Scotece

    SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), the NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Santiago de Compostela, Spain

    13 shared publications
  • Oreste Gualillo

    SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigacion Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital Santiago de Compostela Spain

    13 shared publications
  • Javier Conde

    Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS)

    12 shared publications
  • Jesús Pino

    SERGAS (Servizo Galego de Saude), Division of Orthopaedics Surgery and Traumatology, Santiago University Clinical Hospital, Santiago de Compostela, Spain

    9 shared publications
  • Verónica López

    SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), the NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago University Clinical Hospital, Santiago de Compostela, Spain

    7 shared publications
  • Francisca Lago

    Servizo Galego de Saude, Instituto de Investigación Sanitaria de Santiago, Laboratory of Molecular and Cellular Cardiology, Research Laboratory 7, Santiago University Clinical Hospital, Santiago de Compostela, Spain

    4 shared publications

Latest Publications

  • Open Access

    E74‐like factor 3 and nuclear factor‐κB regulate lipocalin‐2 expression in chondrocytes

    by Javier Conde, Miguel Otero, Morena Scotece, Vanessa Abella, Verónica López, Jesús Pino, Rodolfo Gómez, Francisca Lago, Mary B. Goldring, Oreste Gualillo

    Key points: E74‐like factor 3 (ELF3) is a transcription factor regulated by inflammation in different physio‐pathological situations. Lipocalin‐2 (LCN2) emerged as a relevant adipokine involved in the regulation of inflammation. In this study we showed for the first time the involvement of ELF3 in the control of LCN2 expression and its cooperation with nuclear factor‐κB (NFκB). Our results will help to better understand of the role of ELF3, NFκB and LCN2 in the pathophysiology of articular cartilage. E74‐like factor 3 (ELF3) is a transcription factor induced by inflammatory cytokines in chondrocytes that increases gene expression of catabolic and inflammatory mediators. Lipocalin 2 (LCN2) is a novel adipokine that negatively impacts articular cartilage, triggering catabolic and inflammatory responses in chondrocytes. Here, we investigated the control of LCN2 gene expression by ELF3 in the context of interleukin 1 (IL‐1)‐driven inflammatory responses in chondrocytes. The interaction of ELF3 and nuclear factor‐κB (NFκB) in modulating LCN2 levels was also explored. LCN2 mRNA and protein levels, as well those of several other ELF3 target genes, were determined by RT‐qPCR and Western blotting. Human primary chondrocytes, primary chondrocytes from wild‐type and Elf3 knockout mice, and immortalized human T/C‐28a2 and murine ATDC5 cell lines were used in in vitro assays. The activities of various gene reporter constructs were evaluated by luciferase assays. Gene overexpression and knockdown were performed using specific expression vectors and siRNA technology, respectively. ELF3 overexpression transactivated the LCN2 promoter and increased the IL‐1‐induced mRNA and protein levels of LCN2, as well as the mRNA expression of other pro‐inflammatory mediators, in human and mouse chondrocytes. We also identified a collaborative loop between ELF3 and NFκB that amplifies the induction of LCN2. Our findings show a novel role for ELF3 and NFκB in the induction of the pro‐inflammatory adipokine LCN2, providing additional evidence of the interaction between ELF3 and NFκB in modulating inflammatory responses, and a better understanding of the mechanisms of action of ELF3 in chondrocytes.


  • Open Access

    SERPINE2 Inhibits IL-1α-Induced MMP-13 Expression in Human Chondrocytes: Involvement of ERK/NF-κB/AP-1 Pathways

    by Anna Santoro, Javier Conde, Morena Scotece, Vanessa Abella, Ana Lois, Veronica Lopez, Jesus Pino, Rodolfo Gomez, Juan J Gomez-Reino, Oreste Gualillo

    Osteoarthritis (OA) is a chronic joint disease, characterized by a progressive loss of articular cartilage. During OA, proinflammatory cytokines, such as interleukin IL-1, induce the expression of matrix metalloproteinases (MMPs) in chondrocytes, contributing thus to the extracellular matrix (ECM) degradation. Members of Serpine family, including plasminogen activator inhibitors have been reported to participate in ECM regulation. The aim of this study was to assess the expression of serpin peptidase inhibitor clade E member 2 (SERPINE2), under basal conditions and in response to increasing doses of IL-1α, in human cultured chondrocytes. We also examined the effects of SERPINE2 on IL-1α-induced MMP-13 expression. For completeness, the signaling pathway involved in this process was also explored. SERPINE2 mRNA and protein expression were evaluated by RT-qPCR and western blot analysis in human T/C-28a2 cell line and human primary chondrocytes. These cells were treated with human recombinant SERPINE2, alone or in combination with IL-1α. ERK 1/2, NFκB and AP-1 activation were assessed by western blot analysis. Human cultured chondrocytes express SERPINE2 in basal condition. This expression increased in response to IL-1α stimulation. In addition, recombinant SERPINE2 induced a clear inhibition of MMP-13 expression in IL-1α-stimulated chondrocytes. This inhibitory effect is likely regulated through a pathway involving ERK 1/2, NF-κB and AP-1. Taken together, these data demonstrate that SERPINE2 might prevent cartilage catabolism by inhibiting the expression of MMP-13, one of the most relevant collagenases, involved in cartilage breakdown in OA.


  • Open Access

    Choosing the right chondrocyte cell line: Focus on nitric oxide

    by Anna Santoro, Javier Conde, Morena Scotece, Vanessa Abella, Verónica López, Jesús Pino, Rodolfo Gómez, Juan Jesús Gómez‐Reino, Oreste Gualillo

    Nitric oxide (NO) has been considered a catabolic factor that contributes to OA pathology by inducing chondrocytes apoptosis, matrix metalloproteinases synthesis, and pro‐inflammatory cytokines expression. Thus, the research on NO regulation in chondrocytes represents a relevant field which needs to be explored in depth. However, to date, only the murine ATDC‐5 cell line and primary chondrocytes are well‐established cells to study NO production in cartilage tissues. The goal of this study is to determine whether two commonly used human chondrocytic cell lines: SW‐1353 and T/C‐28a2 cell lines are good models to examine lipopolysaccharide and/or pro‐inflammatory cytokine‐driven NO release and iNOS expression. To this aim, we carefully examined NO production and iNOS protein expression in human T/C‐28a2 and SW‐1353 chondrocytes stimulated with LPS and interleukin (IL)‐1 alone or in combination. We also use ATDC‐5 cells as a positive control for NO production. NO accumulation has been determined by colorimetric Griess reaction, whereas NOS type II expression was determined by Western Blot analysis. Our results clearly demonstrated that neither human T/C‐28a2 nor SW‐1353 chondrocytes showed a detectable increase in NO production or iNOS expression after bacterial endotoxin or cytokines challenge with IL‐1. Our study demonstrated that T/C‐28a2 and SW‐1353 human cell lines are not suitable for studying NO release and iNOS expression confirming that ATDC5 and human primary cultured chondrocytes are the best in vitro cell system to study the actions derived from this mediator. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 33:1784–1788, 2015.


  • Open Access

    Identification of Novel Adipokines in the Joint. Differential Expression in Healthy and Osteoarthritis Tissues

    by Javier Conde, Morena Scotece, Vanessa Abella, Rodolfo Gómez, Verónica López, Rosa Villar, Miguel Hermida, Jesús Pino, Juan Jesús Gómez-Reino, Oreste Gualillo

    Emerging data suggest that several metabolic factors, released mainly by white adipose tissue (WAT) and joint tissues, and collectively named adipokines, might have a role in the pathophysiology of OA. Recently, novel adipokines such as SERPINE2, WISP2, GPNMB and ITIH5 have been identified in WAT. The main goal of this study was to analyse the expression of these novel adipokines in synovium, infrapatellar fat pad and chondrocytes and to compare the expression of these molecules in healthy and OA tissues. Synovial tissues, infrapatellar fat pad and chondrocytes were obtained from 36 OA patients (age 52–85; mean BMI 28.9) who underwent total knee replacement surgery. Healthy synovial tissues and infrapatellar fat pad were obtained from 15 traumatic knee patients (age 23–53; mean BMI 23.5). mRNA and protein expression were determined by qRT-PCR and western blot analysis respectively. All the novel adipokines, matter of our study, are expressed in OA synovium, infrapatellar fat pad and chondrocytes. Moreover, we detected a differential expression of SERPINE2 and ITIH5 in OA synovial tissues as compared to healthy samples. Finally, we also observed an increased expression of WISP2 in OA infrapatellar fat pad in comparison to healthy controls. In this study we demonstrated for the first time the expression of four novel adipokines in different joint tissues and how these molecules are differentially expressed in healthy and OA joint tissues.


  • Non-dioxin-like polychlorinated biphenyls (PCB 101, PCB 153 and PCB 180) induce chondrocyte cell death through multiple pathways

    by Vanessa Abella, Anna Santoro, Morena Scotece, Javier Conde, Verónica López-López, Veronica Lazzaro, Juan Jesus Gómez-Reino, Rosaria Meli, Oreste Gualillo


  • New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history

    by Morena Scotece, Javier Conde, Vanessa Abella, Veronica Lopez, Jesús Pino, Francisca Lago, Amos B. Smith, Juan J. Gómez-Reino, Oreste Gualillo


  • Basic Aspects of Adipokines in Bone Metabolism

    by Javier Conde, Morena Scotece, Vanessa Abella, Verónica López, Jesús Pino, Juan Jesús Gómez-Reino, Oreste Gualillo


  • An update on leptin as immunomodulator

    by Javier Conde, Morena Scotece, Vanessa Abella, Verónica López, Jesús Pino, Juan J Gómez-Reino, Oreste Gualillo

    (2014). An update on leptin as immunomodulator. Expert Review of Clinical Immunology: Vol. 10, No. 9, pp. 1165-1170. doi: 10.1586/1744666X.2014.942289


  • Bone metabolism and adipokines: are there perspectives for bone diseases drug discovery?

    by Morena Scotece, Javier Conde, Vanessa Abella, Verónica López, Jesús Pino, Francisca Lago, Juan J Gómez-Reino, Oreste Gualillo

    Over the past 20 years, the idea that white adipose tissue (WAT) is simply an energy depot organ has been radically changed. Indeed, present understanding suggests WAT to be an endocrine organ capable of producing and secreting a wide variety of proteins termed adipokines. These adipokines appear to be relevant factors involved in a number of different functions, including metabolism, immune response, inflammation and bone metabolism. In this review, the authors focus on the effects of several adipose tissue-derived factors in bone pathophysiology. They also consider how the modification of the adipokine network could potentially lead to promising treatment options for bone diseases. There are currently substantial developments being made in the understanding of the interplay between bone metabolism and the metabolic system. These insights could potentially lead to the development of new treatment strategies and interventions with the aim of successful outcomes in many people affected by bone disorders. Specifically, future research should look into the intimate mechanisms regulating peripheral and central activity of adipokines as it has potential for novel drug discovery.


  • IL-36α: a novel cytokine involved in the inflammatory response in human chondrocytes

    by J. Conde, M. Scotece, V. Abella, V. Lopez, V. Lazzaro, J. Pino, J.J. Gomez-Reino, O. Gualillo